PRAX Latest Press Releases

-- November 4, 2026 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- October 27, 2026 --

Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation Globe Newswire 4:01 PM

-- October 2, 2026 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- September 3, 2026 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:05 PM

-- August 6, 2026 --

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2026 Financial Results Globe Newswire 8:00 AM

-- August 4, 2026 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- July 30, 2026 --

Praxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026 Globe Newswire 4:01 PM

-- July 7, 2026 --

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor Globe Newswire 8:00 AM

-- July 2, 2026 --

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Globe Newswire 4:01 PM

-- June 29, 2026 --

Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies Globe Newswire 4:30 PM

-- June 22, 2026 --

Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Elsunersen for the Treatment of Seizures Associated with SCN2A Developmental and Epileptic Encephalopathy Caused by Gain of Function Variants Globe Newswire 8:00 AM

Market Data Delayed 15 Minutes